- A radiation-emitting "GammaTile" implanted at the brain-tumor site during surgery greatly cut local regrowth (about 1% vs ~12%) and improved two-year survival versus standard post-op radiation.
- J&J’s bispecific antibody Tecvayli produced much deeper, longer remissions in relapsed multiple myeloma — nearly 70% progression-free at 18 months and about two-thirds of patients reached complete remission versus ~17% with standard care.
- Moderna’s personalized mRNA vaccine (intismeran) plus Merck’s Keytruda roughly halved melanoma recurrence at five years (disease-free ~69% vs ~49%) and raised overall survival (92% vs 71%) compared with Keytruda alone.
The news, distilled into what matters.
Get the full experience in the app — topics, comments, and audio summaries.